China National Accord Medicines Future Growth

Future criteria checks 1/6

China National Accord Medicines is forecast to grow earnings and revenue by 6.6% and 5.7% per annum respectively. EPS is expected to grow by 6.5% per annum. Return on equity is forecast to be 8.4% in 3 years.

Key information

6.6%

Earnings growth rate

6.5%

EPS growth rate

Healthcare earnings growth	21.4%
Revenue growth rate	5.7%
Future return on equity	8.4%
Analyst coverage	Good
Last updated	13 Sep 2024

Recent future growth updates

Analysts Are Updating Their China National Accord Medicines Corporation Ltd. (SZSE:000028) Estimates After Its Full-Year Results

Apr 10

Recent updates

China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Low P/E No Reason For Excitement

Aug 13

Estimating The Intrinsic Value Of China National Accord Medicines Corporation Ltd. (SZSE:000028)

Jul 12

Is China National Accord Medicines (SZSE:000028) A Risky Investment?

Jun 12

Improved Earnings Required Before China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Find Their Feet

May 12

Analysts Are Updating Their China National Accord Medicines Corporation Ltd. (SZSE:000028) Estimates After Its Full-Year Results

Apr 10

China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Could Be 28% Below Their Intrinsic Value Estimate

Mar 15

China National Accord Medicines (SZSE:000028) Has A Rock Solid Balance Sheet

Feb 29

Earnings and Revenue Growth Forecasts

SZSE:000028 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	85,892	1,737	N/A	1,736	6
12/31/2025	82,386	1,645	N/A	1,741	7
12/31/2024	76,655	1,436	N/A	2,944	5
6/30/2024	74,876	1,512	2,073	2,380	N/A
3/31/2024	75,881	1,626	1,769	2,093	N/A
12/31/2023	75,477	1,599	2,615	2,937	N/A
9/30/2023	75,412	1,629	1,656	1,968	N/A
6/30/2023	75,702	1,643	2,674	3,005	N/A
3/31/2023	74,979	1,597	2,672	2,988	N/A
12/31/2022	73,443	1,487	2,238	2,560	N/A
9/30/2022	72,765	1,310	1,931	2,293	N/A
6/30/2022	71,324	1,269	1,098	1,467	N/A
3/31/2022	69,459	1,260	1,360	1,744	N/A
12/31/2021	68,358	1,336	1,285	1,655	N/A
9/30/2021	66,979	1,478	592	939	N/A
6/30/2021	65,643	1,500	970	1,294	N/A
3/31/2021	62,875	1,482	1,579	1,884	N/A
12/31/2020	59,649	1,402	1,209	1,503	N/A
9/30/2020	56,244	1,306	2,663	2,937	N/A
6/30/2020	54,358	1,262	2,058	2,312	N/A
3/31/2020	53,539	1,217	1,865	2,113	N/A
12/31/2019	52,787	1,268	1,761	2,013	N/A
9/30/2019	50,779	1,243	1,546	1,817	N/A
6/30/2019	47,943	1,218	1,965	2,236	N/A
3/31/2019	44,937	1,217	1,140	1,399	N/A
12/31/2018	43,122	1,211	1,067	1,323	N/A
9/30/2018	41,751	1,182	1,110	1,338	N/A
6/30/2018	41,517	1,143	1,062	1,282	N/A
3/31/2018	41,298	1,078	N/A	923	N/A
12/31/2017	41,263	1,058	N/A	1,285	N/A
9/30/2017	41,418	1,080	N/A	1,155	N/A
6/30/2017	41,211	1,084	N/A	871	N/A
3/31/2017	41,159	1,205	N/A	959	N/A
12/31/2016	41,248	1,187	N/A	1,472	N/A
9/30/2016	49,249	1,263	N/A	1,878	N/A
6/30/2016	45,568	1,199	N/A	1,839	N/A
3/31/2016	41,870	984	N/A	1,286	N/A
12/31/2015	37,819	928	N/A	1,457	N/A
9/30/2015	25,740	721	N/A	201	N/A
6/30/2015	25,155	693	N/A	136	N/A
3/31/2015	24,683	682	N/A	-189	N/A
12/31/2014	23,954	652	N/A	-797	N/A
9/30/2014	23,418	629	N/A	-369	N/A
6/30/2014	22,680	607	N/A	-258	N/A
3/31/2014	21,864	545	N/A	-70	N/A
12/31/2013	21,199	520	N/A	465	N/A
9/30/2013	20,192	515	N/A	557	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 000028's forecast earnings growth (6.6% per year) is above the savings rate (2.9%).

Earnings vs Market: 000028's earnings (6.6% per year) are forecast to grow slower than the CN market (22.9% per year).

High Growth Earnings: 000028's earnings are forecast to grow, but not significantly.

Revenue vs Market: 000028's revenue (5.7% per year) is forecast to grow slower than the CN market (13.1% per year).

High Growth Revenue: 000028's revenue (5.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 000028's Return on Equity is forecast to be low in 3 years time (8.4%).

China National Accord Medicines Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 14%

Price target decreased by 8.4% to CN¥35.86

Analysts Are Updating Their China National Accord Medicines Corporation Ltd. (SZSE:000028) Estimates After Its Full-Year Results

Price target decreased by 11% to CN¥36.44

Price target decreased by 10% to CN¥42.49

Price target increased by 16% to CN¥42.59

Recent updates

Consensus EPS estimates fall by 14%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 8.4% to CN¥35.86

China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Low P/E No Reason For Excitement

High number of new directors

Estimating The Intrinsic Value Of China National Accord Medicines Corporation Ltd. (SZSE:000028)

Insufficient new directors

China National Accord Medicines Corporation Ltd. to Report First Half, 2024 Results on Aug 28, 2024

China National Accord Medicines Corporation Ltd. Announces Final Cash Dividend on B Shares for the Year 2023, Payable on 27 June 2024

Is China National Accord Medicines (SZSE:000028) A Risky Investment?

Improved Earnings Required Before China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Find Their Feet

China National Accord Medicines Corporation Ltd. Approves Cash Dividend for the Year 2023

Now 20% overvalued after recent price rise

Analysts Are Updating Their China National Accord Medicines Corporation Ltd. (SZSE:000028) Estimates After Its Full-Year Results

Full year 2023 earnings: EPS and revenues miss analyst expectations

China National Accord Medicines Corporation Ltd., Annual General Meeting, May 08, 2024

China National Accord Medicines Corporation Ltd. to Report Q1, 2024 Results on Apr 30, 2024

China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Could Be 28% Below Their Intrinsic Value Estimate

China National Accord Medicines (SZSE:000028) Has A Rock Solid Balance Sheet

Investor sentiment improves as stock rises 17%

China National Accord Medicines Corporation Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Now 20% undervalued after recent price drop

Price target decreased by 11% to CN¥36.44

Now 22% undervalued after recent price drop

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 10% to CN¥42.49

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 16% to CN¥42.59

Full year 2022 earnings released: EPS: CN¥3.47 (vs CN¥3.12 in FY 2021)

Investor sentiment improves as stock rises 18%

Price target increased by 7.0% to CN¥38.16

Now 21% undervalued

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings released: EPS: CN¥0.98 (vs CN¥0.96 in 2Q 2021)

China National Accord Medicines Corporation Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on June 17, 2022

Price target decreased to CN¥38.17

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

China National Accord Medicines Corporation Ltd. Approves Final Cash Dividend for the Year 2021

China National Accord Medicines Corporation Ltd., Annual General Meeting, Apr 22, 2022

China National Accord Medicines Corporation Ltd. Proposes Final Cash Dividend for the Year 2021

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS CN¥0.96 (vs CN¥0.92 in 2Q 2020)

Price target decreased to CN¥52.97

High number of new directors

Upcoming dividend of CN¥0.80 per share

First quarter 2021 earnings released: EPS CN¥0.77 (vs CN¥0.58 in 1Q 2020)

Consensus forecasts updated

Full year 2020 earnings released: EPS CN¥3.27 (vs CN¥2.97 in FY 2019)

China National Accord Medicines Corporation Ltd. to Report Fiscal Year 2020 Results on Apr 16, 2021

New 90-day low: CN¥41.98

New 90-day low: CN¥46.01

New 90-day high: CN¥51.91

Price target raised to CN¥60.27

Third quarter earnings released

China National Accord Medicines Corporation Ltd. to Report Q3, 2020 Results on Oct 22, 2020

First half earnings released

Earnings released

China National Accord Medicines Corporation Ltd. to Report First Half, 2020 Results on Aug 29, 2020

New 90-day high - CN¥51.20

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies